GENEVA — A deal on an intellectual property waiver for COVID-19 vaccines at the World Trade Organization (WTO) was no closer to acceptance on Monday despite Washington’s backing, due to expected skepticism about a new draft, sources close to the talks told Reuters.
Negotiations reopened at the WTO on Monday, focused on a highly anticipated revised draft submitted by India, South Africa and dozens of other developing countries last week.
A surprise U.S. shift earlier this month to support a patent waiver heaped pressure on remaining opponents like the European Union and Switzerland that are home to numerous drugmakers. But Monday’s discussions – the 11th session since the init…
Keep on reading: Even after US shift, opponents resist COVID-19 vaccine patent waiver